Ensysce Biosciences, Inc.
ENSC Nasdaq
SEC CIK 1716947
Follow Ensysce Biosciences
Weekly email: filings, results
Revenue, last quarter
$2.2M
+342.4% vs same quarter last year
Net income
−$82.1M
−2102% vs same quarter last year
EPS, diluted
−$4.52
−250.4% vs same quarter last year
Operating cash flow
−$1.4M
+25.2% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $5.1M | −$10.2M |
| FY24 | $5.2M | −$8M |
| FY23 | $2.2M | −$10.6M |
| FY22 | $2.5M | −$24.2M |
| FY21 | $3.5M | −$29.1M |
| FY20 | $3.9M | $4.3M |
| FY19 | - | −$1.1M |
| FY18 | - | - |
| FY17 | - | - |
- Operating margin
- Net margin
Show the numbers
| Year | Operating margin | Net margin |
|---|---|---|
| FY25 | −202.1% | −200.8% |
| FY24 | −129.2% | −153.3% |
| FY23 | −480.5% | −476.4% |
| FY22 | −959.9% | −959.3% |
| FY21 | −562.7% | −825.4% |
| FY20 | −41% | 109.7% |
| FY19 | - | - |
| FY18 | - | - |
| FY17 | - | - |
- Ensysce Biosciences
- Healthcare median
Show the numbers
| Year | Ensysce Biosciences | Healthcare median |
|---|---|---|
| FY25 | −200.8% | −30.6% |
| FY24 | −153.3% | −47% |
| FY23 | −476.4% | −58% |
| FY22 | −959.3% | −80.4% |
| FY21 | −825.4% | −71.8% |
| FY20 | 109.7% | −62.2% |
| FY19 | - | −46.2% |
| FY18 | - | −49.6% |
| FY17 | - | −45.9% |